Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jun 9;5(2):29.
doi: 10.3390/biomedicines5020029.

NF-κB Signalling in Glioblastoma

Affiliations
Review

NF-κB Signalling in Glioblastoma

Vincent Soubannier et al. Biomedicines. .

Abstract

Nuclear factor-κB (NF-κB) is a transcription factor regulating a wide array of genes mediating numerous cellular processes such as proliferation, differentiation, motility and survival, to name a few. Aberrant activation of NF-κB is a frequent event in numerous cancers, including glioblastoma, the most common and lethal form of brain tumours of glial cell origin (collectively termed gliomas). Glioblastoma is characterized by high cellular heterogeneity, resistance to therapy and almost inevitable recurrence after surgery and treatment. NF-κB is aberrantly activated in response to a variety of stimuli in glioblastoma, where its activity has been implicated in processes ranging from maintenance of cancer stem-like cells, stimulation of cancer cell invasion, promotion of mesenchymal identity, and resistance to radiotherapy. This review examines the mechanisms of NF-κB activation in glioblastoma, the involvement of NF-κB in several mechanisms underlying glioblastoma propagation, and discusses some of the important questions of future research into the roles of NF-κB in glioblastoma.

Keywords: DNA damage repair; NF-κB (nuclear factor-κB); brain cancer; cancer stem-like cells; glioblastoma; mesenchymal glioblastoma subtype.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Omuro A., DeAngelis L.M. Glioblastoma and other malignant gliomas: A clinical review. JAMA. 2013;310:1842–1850. doi: 10.1001/jama.2013.280319. - DOI - PubMed
    1. Aldape K., Zadeh G., Mansouri S., Reifenberger G., von Deimling A. Glioblastoma: Pathology, molecular mechanisms and markers. Acta Neuropathol. 2015;129:829–848. doi: 10.1007/s00401-015-1432-1. - DOI - PubMed
    1. Ellis H.P., Greenslade M., Powell B., Spiteri I., Sottoriva A., Kurian K.M. Current challenges in glioblastoma: Intratumour heterogeneity, residual disease, and models to predict disease recurrence. Front. Oncol. 2015;5:251. doi: 10.3389/fonc.2015.00251. - DOI - PMC - PubMed
    1. Schneider M., Ströbele S., Nonnenmacher L., Siegelin M.D., Tepper M., Stroh S., Hasslacher S., Enzenmüller S., Strauss G., Baumann B., et al. A paired comparison between glioblastoma “stem cells” and differentiated cells. Int. J. Cancer. 2016;138:1709–1718. doi: 10.1002/ijc.29908. - DOI - PubMed
    1. Bonavia R., Inda M.M., Cavenee W.K., Furnari F.B. Heterogeneity maintenance in glioblastoma: A social network. Cancer Res. 2011;71:4055–4060. doi: 10.1158/0008-5472.CAN-11-0153. - DOI - PMC - PubMed